Masahito Jimbo is Professor of Family Medicine and Urology at the University of Michigan. Having worked as a family physician in both urban (Philadelphia) and rural (North Carolina) underserved areas, he has first-hand knowledge and experience of the challenges faced by clinicians and healthcare institutions to be successful in providing patient care that is personal, comprehensive, efficient and timely. Initially trained in basic laboratory research, having obtained his MD and PhD degrees at Keio University in Tokyo, Japan, Dr.
Page not found
Darin Zahuranec and Kunal Bailoor (medical student) are developing a project for Kunal’s Bioethics Path of Excellence capstone project to investigate the acceptability of physician paternalism in decisions on life-sustaining treatments after stroke.
Brian will speak about Preliminary data from a study looking at how to graphically present historical test result data with current test results.
Wendy R. Uhlmann, MS, CGC is the genetic counselor/clinic coordinator of the Medical Genetics Clinic at the University of Michigan. She is a Clinical Professor in the Departments of Internal Medicine and Human Genetics and an executive faculty member of the genetic counseling training program. Wendy Uhlmann is a Past President of the National Society of Genetic Counselors and previously served on the Board of Directors of the Genetic Alliance and as NSGC’s liaison to the National Advisory Council for Human Genome Research.
Carl E. Schneider is the Chauncey Stillman Professor for Ethics, Morality, and the Practice of Law and is a Professor of Internal Medicine. He was educated at Harvard College and the University of Michigan Law School, where he was editor in chief of the Michigan Law Review. He served as law clerk to Judge Carl McGowan of the United States Court of Appeals for the District of Columbia Circuit and to Justice Potter Stewart of the United States Supreme Court. He became a member of the Law School faculty in 1981 and of the Medical School faculty in 1998.
Imagine you just had a medical test or treatment. You are asked to donate your leftover tissue to a biobank.
Biobanks store donated samples, like blood, urine, skin, or tumor cells. Researchers can ask the biobank if they can use some of the samples to do their studies. These samples may help researchers to find better ways of preventing or treating disease.
You are asked to sign a “blanket consent” form. This means that the biobank can use your sample in any study done by researchers who use the biobank.
The biobank cannot predict what kind of studies will be done in the future. However, a committee must review each study to make sure the study is well designed, protects your privacy, and will help society.
Imagine that you are a patient with end-stage liver disease and you are currently on the liver transplant waiting list.
Available donor livers are limited and vary in quality. Donor characteristics such as age and cause of death can make a difference between a 20% and a 40% rate of liver transplant (graft) failure by 3-years post-transplant.
Now imagine that you and your doctor are discussing the risks and benefits of a liver transplant and whether you might consider a “less than perfect” liver (with a higher risk for graft failure). To help you in your decision making, you are provided with a decision aid to help you to consider the level of risk you would be willing to accept from a donated liver.
On the following page, consider an image representing your (pretend!) risk of dying or becoming too sick for a liver transplant within the next 3-months if you don’t get a transplant.